Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences BioMEMS, Microfluidics & Biofabrication: Technologies and Applications

Gabor Forgacs's Biography

Gabor Forgacs, Professor, University of Missouri-Columbia; Scientific Founder, Organovo; CSO, Modern Meadow

Dr. Gabor Forgacs is a theoretical physicist turned bioengineer turned innovator and entrepreneur. He is the George H. Vineyard Professor of Biological Physics at the University of Missouri-Columbia, the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and scientific founder of Organovo, Inc. and Modern Meadow, Inc. He was trained as a theoretical physicist at the Roland Eotvos University, Budapest, Hungary and the Landau Institute of Theoretical Physics, Moscow, USSR. He also has a degree in biology. His research interests span from topics in theoretical physics to physical mechanisms in early embryonic development. He is the co-author of the celebrated text in the field, “Biological Physics of the Developing Embryo” (Cambridge University Press, 2005) that discusses the fundamental morphogenetic mechanisms evident in early development. These mechanisms are being applied to building living structures of prescribed shape and functionality using bioprinting, a novel tissue engineering technology he pioneered. He is the author of over 160 peer-reviewed scientific articles and 5 books. He has been recognized by numerous awards and citations. In particular, he was named as one of the “100 most innovative people in business in 2010” by FastCompany.

Gabor Forgacs Image

Monitoring Biological Processes In Situ: Lab-in-the-Tissue

Thursday, 16 March 2017 at 09:30

Add to Calendar ▼2017-03-16 09:30:002017-03-16 10:30:00Europe/LondonMonitoring Biological Processes In Situ:

Engineering of 3D tissues and organs has seen spectacular progress in recent years. The technologies of 3D-printing and organ-­on-the chip have provided invaluable tools and structures for basic research, drug toxicity assays or disease models. In the case of drug toxicity studies the engineered construct is typically subjected to either known drugs or to new candidate drugs and metabolic functions are measured by detection of metabolites in the culture medium in which the engineered construct resides. This type of monitoring however, reveals only limited information about how the internal structure (e.g. cell-­cell interactions) of the engineered construct is effected and thus about the suitability of the tissue for further applications, such as its use in disease studies or ultimately for implantation. Here we propose to combine 3D printing and BioMEMS and related technologies to build Lab-in-the-­tissue devices for the in situ monitoring of metabolic and functional properties of engineered tissues and organ structures.

Add to Calendar ▼2017-03-16 00:00:002017-03-17 00:00:00Europe/LondonBioMEMS, Microfluidics and Biofabrication: Technologies and